Potential Benefits of Adding Alendronate, Celecoxib, Itraconazole, Ramelteon, and Simvastatin to Endometrial Cancer Treatment: The EC5 Regimen
Current Issues in Molecular Biology,
Journal Year:
2025,
Volume and Issue:
47(3), P. 153 - 153
Published: Feb. 26, 2025
Metastatic
endometrial
cancer
continues
to
be
a
common
cause
of
death
as
2024,
even
after
maximal
use
all
currently
available
standard
treatments.
To
address
this
problem
metastatic
generally
in
2025,
the
drug
repurposing
movement
within
oncology
identifies
medicines
general
medical
that
have
clinical
or
preclinical
experimental
data
indicating
they
interfere
with
inhibit
specific
growth
driving
element
identified
given
cancer.
The
also
uses
from
large
scale
vitro
screens
thousands
drugs,
looking
for
simple
empirical
inhibition
type.
This
paper
outlines
showing
five
drugs
practice
meet
these
evidence
criteria
growth,
EC5
regimen.
regimen
osteoporosis
treatment
drug,
alendronate;
analgesic
celecoxib;
antifungal
itraconazole;
sleep
aid,
ramelteon;
and
cholesterol
lowering
simvastatin.
Side
effects
seen
are
usually
minimal
easily
tolerated
by
patients.
Language: Английский
UBC4: A Repurposed Drug Regimen for Adjunctive Use During Bladder Cancer Treatment
Biomedicines,
Journal Year:
2025,
Volume and Issue:
13(3), P. 706 - 706
Published: March 13, 2025
After
it
has
metastasized,
bladder
cancer,
the
malignant
transformation
of
urothelium,
continues
to
be
a
common
cause
death
after
maximal
use
all
currently
available
standard
treatments.
To
address
this
problem
in
2025,
drug
repurposing
movement
within
oncology
aims
identify
medicines
general
medical
care
that
have
data
indicating
they
can
interfere
or
inhibit
growth
driving
element
been
identified
cancer.
This
paper
now
outlines
extensive
preclinical
showing
four
drugs
from
practice
meet
these
criteria—the
melatonergic
ramelteon,
antidepressant
fluoxetine,
antibiotic
dapsone,
and
analgesic
celecoxib.
is
UBC4
regimen,
meant
as
possible
adjunct
added
treatments
metastatic
Three
factors
justify
clinical
pilot
trial
UBC4:
(1)
are
usually
well
tolerated
carry
low
risk
harm,
(2)
commonly
fatal
outcome
cancer
once
widely
plus
(3)
strong
database
UBC
inhibition
by
each
individual
outlined
paper.
Language: Английский
Reducing Brain Edema Using Berotralstat, an Inhibitor of Bradykinin, Repurposed as Treatment Adjunct in Glioblastoma
Neuroglia,
Journal Year:
2024,
Volume and Issue:
5(3), P. 223 - 233
Published: July 2, 2024
Glioblastomas
synthesize,
bear
receptors
for,
and
respond
to
bradykinin,
triggering
migration
proliferation.
Since
centrifugal
into
uninvolved
surrounding
brain
tissue
occurs
early
in
the
course
of
glioblastoma,
this
attribute
defeats
local
treatment
attempts
is
primary
reason
current
treatments
almost
always
fail.
Stopping
bradykinin-triggered
would
be
a
step
closer
control
disease.
The
recent
approval
marketing
an
oral
plasma
kallikrein
inhibitor,
berotralstat
(Orladeyo™),
pending
FDA
similar
drug,
sebetralstat,
now
offers
potential
method
for
reducing
bradykinin
production
at
sites
bradykinin-mediated
glioblastoma
migration.
Both
drugs
are
approved
treating
hereditary
angioedema.
They
ideal
repurposing
as
adjunct
glioblastoma.
Furthermore,
it
has
been
established
that
peritumoral
edema,
common
problem
during
clinical
generated
large
part
by
locally
produced
via
action.
edema
consequent
use
corticosteroids
both
shorten
survival
Therefore,
(i)
inhibition,
(ii)
growth
(iii)
reduction,
(iv)
less
corticosteroids,
may
service
slowing
disease
progression.
This
paper
recounts
details
past
research
on
rationale
with
berotralstat.
Language: Английский